Gilead Sciences Inc., seeking its second significant product approval in a year, is going before an FDA advisory panel today that is expected to issue a recommendation on Gilead's new drug application for adefovir dipivoxil, a once-daily oral treatment for hepatitis B. (BioWorld Today) Read More
